The NETTER-2 trial provides the first phase III evidence that 177Lu-dotatate is active as first-line therapy in patients with gastroenteropancreatic neuroendocrine tumours with a Ki-67 proliferative index of 10–55%. This approach is an important addition to the first-line therapeutic armamentarium, although treatment selection based on patient-specific and tumour-specific characteristics remains appropriate.

中文翻译：

---

NETTER-2 是一项改变实践的试验吗？


NETTER-2 试验提供了第一个 III 期证据，表明 177Lu-dotatate 作为 Ki-67 增殖指数为 10-55% 的胃肠胰神经内分泌肿瘤患者的一线治疗有效。尽管基于患者特异性和肿瘤特异性特征的治疗选择仍然是适当的，但这种方法是对一线治疗装备的重要补充。